Cancer Generics $CGIX a top performing IPO

$CGIX went public in April at $10 and hits $22 almost 6mo later. Focused on DNA probes for cancer diagnostics and drug/treatment monitoring. Backing by the "Buffet" of biotech John PappaJohn, strong received  buy rating from Aegis w/ $25 target, pharma partnerships expand. (Disclosure: am early holder and long) 

3 comments:

Healthcare India said...

Congratulations on having one of the most sophisticated blogs I’ve come across in some time! It’s just incredible how much you can take away from something simply because of how visually beautiful it is..

orthopedic doctor

High blood pressure said...

Well written about cancer generics..really bio technologies are boon for recent life style

Harlin Quincy said...

I am glad that there is so much biotech research going into cancer. It is a problem that needs to be dealt with.